Orient Pharma Co (4166.TWO) Stock Price

Orient Pharma Co Price

CLOSED
23.40
​
Market closed

Revenue has compounded at 19.3% per year over the past 15 years to 1.40 B TWD. Earnings per share have grown at 193.0% per year over the last 2 years. Orient Pharma Co's net margin stands at 14.9%, up from -22.2% several years earlier.

Orient Pharma Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Pharma Co business model & stock analysis

Orient Pharma Co., Ltd. engages in the research, development, and production of pharmaceutical products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2012-06-15. The firm's main products include hyperlipidemic drugs, diabetes drugs, cardiovascular drugs and drugs for musculoskeletal diseases. The firm is also involved in the original equipment manufacturer (OEM) manufacturing business and clinical trial business. The firm distributes its products in domestic market and to overseas markets, such as the United States, Ireland and mainland China.

Frequently asked questions about Orient Pharma Co

Converted at the current exchange rate, the Orient Pharma Co share trades at 0.64 EUR (23.40 TWD).

The revenue cannot currently be calculated for Orient Pharma Co.

The profit cannot currently be calculated for Orient Pharma Co.

The P/E ratio cannot be calculated for Orient Pharma Co at the moment.

The P/S cannot be calculated for Orient Pharma Co currently.

The Eulerpool Quality Score for Orient Pharma Co is 6/10.

The ISIN of Orient Pharma Co is TW0004166004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Orient Pharma Co is 4166.TWO. The ticker symbol is used to trade Orient Pharma Co shares on the stock exchange.

Fair ValueTerminal
21.76 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
66.68 M TWD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website oppharma.com
Country
Taiwan
Currency
TWD
Initial public offering
Jun 15, 2012
ISIN
TW0004166004
Cusip
Y6S85J106
Market capitalization
5.69 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
19.09
P/B Ratio
2.22
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
8.13 %
Last updated Nov 2, 2026, 10:11 PM

Orient Pharma Co Peer Group

Orient Pharma Co FIGI

4166:TT (Taipei Stock Exchange) · BBG0033966J0

All fundamentals and in-depth analysis of Orient Pharma Co

Our stock analysis for Orient Pharma Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orient Pharma Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.